| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2067 | 2017 |
| Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 … T Powles, I Durán, MS Van der Heijden, Y Loriot, NJ Vogelzang, ... The Lancet 391 (10122), 748-757, 2018 | 1351 | 2018 |
| Erdafitinib in locally advanced or metastatic urothelial carcinoma Y Loriot, A Necchi, SH Park, J Garcia-Donas, R Huddart, E Burgess, ... New England Journal of Medicine 381 (4), 338-348, 2019 | 1095 | 2019 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 705 | 2019 |
| Enfortumab vedotin in previously treated advanced urothelial carcinoma T Powles, JE Rosenberg, GP Sonpavde, Y Loriot, I Durán, JL Lee, ... New England Journal of Medicine 384 (12), 1125-1135, 2021 | 624 | 2021 |
| Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial T Powles, M Kockx, A Rodriguez-Vida, I Duran, SJ Crabb, ... Nature medicine 25 (11), 1706-1714, 2019 | 474 | 2019 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 382 | 2020 |
| Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020 | 355 | 2020 |
| Biomarkers of response to PD-1/PD-L1 inhibition SM Vareki, C Garrigós, I Duran Critical reviews in oncology/hematology 116, 116-124, 2017 | 316 | 2017 |
| Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution … V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ... Annals of Oncology 28 (7), 1508-1516, 2017 | 265 | 2017 |
| Systemic therapy for non–clear cell renal cell carcinomas: a systematic review and meta-analysis FE Vera-Badillo, AJ Templeton, I Duran, A Ocana, P de Gouveia, P Aneja, ... European urology 67 (4), 740-749, 2015 | 205 | 2015 |
| Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus I Duran, LL Siu, AM Oza, TB Chung, J Sturgeon, CA Townsley, GR Pond, ... European Journal of Cancer 42 (12), 1875-1880, 2006 | 193 | 2006 |
| Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection R Garcia-Carbonero, R Salazar, I Duran, I Osman-Garcia, L Paz-Ares, ... Journal for immunotherapy of cancer 5, 1-13, 2017 | 153 | 2017 |
| Systemic treatment of renal cell cancer: A comprehensive review A Sánchez-Gastaldo, E Kempf, AG Del Alba, I Duran Cancer treatment reviews 60, 77-89, 2017 | 149 | 2017 |
| Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia A Jimeno, A García‐Velasco, O del Val, E González‐Billalabeitia, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2004 | 148 | 2004 |
| Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors LL Siu, R Pili, I Duran, WA Messersmith, EX Chen, R Sullivan, M MacLean, ... Journal of clinical oncology: official journal of the American Society of …, 2008 | 139 | 2008 |
| Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE) E Grande, J Capdevila, D Castellano, A Teulé, I Durán, J Fuster, I Sevilla, ... Annals of oncology 26 (9), 1987-1993, 2015 | 135 | 2015 |
| Chromophobe renal cell carcinoma: a review of an uncommon entity FE Vera‐Badillo, E Conde, I Duran International Journal of Urology 19 (10), 894-900, 2012 | 132 | 2012 |
| Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the … CN Sternberg, Y Loriot, N James, E Choy, D Castellano, F Lopez-Rios, ... European urology 76 (1), 73-81, 2019 | 131 | 2019 |
| Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma MI Milowsky, C Dittrich, I Durán, S Jagdev, FE Millard, CJ Sweeney, ... European journal of cancer 50 (18), 3145-3152, 2014 | 123 | 2014 |
